Clinical data released from trials of depemokimab, an IL‑5–targeting monoclonal antibody, report a favorable safety profile when dosed twice yearly for patients with asthma and chronic rhinosinusitis with nasal polyps. Investigators found the extended dosing interval maintained tolerability while achieving pharmacodynamic effects consistent with IL‑5 pathway inhibition. The data support a low‑frequency administration model that could improve adherence and reduce treatment burden compared with more frequent biologic injections. Sponsors are evaluating whether the safety and dosing convenience could translate into differentiated commercial positioning versus established anti‑IL‑5 therapies. Regulatory filings will hinge on confirmatory efficacy data and longer‑term safety follow‑up, but the safety signal positions depemokimab as a candidate in the increasingly competitive severe‑asthma biologic market.